https://www.live-feeds.com/feed/crispr-gene-editing-therapy-safely-and-continuously-lowers-cholesterol-and-triglycerides-first-in-human-trial-showsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/crispr-gene-editing-therapy-safely-and-continuously-lowers-cholesterol-and-triglycerides-first-in-human-trial-showshttps://www.live-feeds.com/feed/crispr-gene-editing-therapy-safely-and-continuously-lowers-cholesterol-and-triglycerides-first-in-human-trial-shows#u60619Mon, 07 Sep 2026 22:40:10 +0000A first-in-human trial of an experimental one-dose CRISPR gene-editing therapy reduced bad cholesterol by 52%. The treatment safely and continuously lowers both cholesterol and triglycerides. Data from the CTX310 candidate has impressed analysts, though some suggest the stock value of CRISPR Therapeutics is now fully reflected in its current price. The therapy represents a shift toward permanent genetic modifications to manage lipid levels rather than relying on daily medications or recurring injections.Why it mattersHigh cholesterol and triglycerides are primary risk factors for cardiovascula